Atlanta-based CeloNova BioSciences today in October 2006 that it has a technological solution for the serious thrombosis problems facing drug-eluting stents. The solution is the patented, medically inert Polyzene(R)-F stent coating.

Polyzene(R)-F prevents thrombosis and promotes normal endothelial cell growth. Interventional physicians will soon be able to minimize restenosis without resorting to drug-eluting stents that can cause thromboses and heart attack.

Long term studies now suggest that a small number (2-6%) of these drug-eluting stents are associated with a rare but catastrophic risk for thrombosis. Nearly 50% of patients with a drug-eluting stent thrombosis die from the effects of the blood clot. This increased risk of blood clots and deaths is apparently caused by the drugs
interference with the normal blood vessel wall healing process in which new
endothelial cells grow over the site of the stent implant as the stent is
integrated into the structure of the artery. In contrast to this interference from drugs, in animal studies and human clinical trials, Polyzene(R)-F actually promoted healthy endothelial cell growth.

And, in contrast to the clot-inducing potential of bare metal stents, the
Polyzene(R)-F coating inhibits the adhesion and activation of coagulation factors that can produce clots.